Icad INC

RadNet, Inc.'s wholly-owned subsidiary, DeepHealth, has completed the acquisition of iCAD, Inc., integrating iCAD's AI-powered breast health solutions to enhance DeepHealth's market position and accelerate AI adoption globally.

iCAD, Inc. stockholders have approved the Agreement and Plan of Merger with RadNet, Inc., paving the way for the acquisition to close on July 17, 2025.

iCAD's Board of Directors approved an amendment to the exercise provisions of certain stock options in connection with the pending merger with RadNet, Inc.

iCAD, Inc. announced its Q1 2025 financial results, highlighting a flat revenue year-over-year but improved gross margins and progress in its transition to cloud-based solutions, while also noting a pending acquisition by RadNet.

RadNet will acquire iCAD in an all-stock transaction valued at approximately $103 million, combining their AI-powered breast cancer detection and workflow solutions.

iCAD, Inc. announces its Q4 and full-year 2024 financial results, highlighting a 14% increase in total revenues and an 11% rise in Annual Recurring Revenue (ARR) as it transitions to a SaaS-based model.

iCAD, Inc. announces its Q1 2025 financial results, highlighting a slight revenue decrease and a pending merger agreement with RadNet, Inc.

iCAD Inc. saw a 3.5% increase in total revenue for the third quarter of 2024, driven by a 14.1% rise in product revenue, while service revenue declined by 8.9%.

iCAD Inc. has filed an amendment to its quarterly report to correct the filing date of the original report.

iCAD Inc. saw a 20.6% increase in total revenue in the second quarter of 2024 compared to the same period last year, primarily due to higher product sales.

iCAD Inc. saw a 14.3% increase in total revenue year-over-year in the first quarter of 2024, driven by higher product sales.

iCAD, Inc. files an amendment to its 2024 annual report on Form 10-K to restate information regarding directors, executive compensation, security ownership, related transactions, and accounting fees, while also addressing certifications and the pending merger with RadNet.

iCAD Inc. reports a 13.2% increase in revenue for 2024, driven by growth in product and license sales and strategic initiatives.

iCAD, Inc.'s 10-K filing outlines its capital structure, regulatory environment, and strategic shift towards a SaaS model, emphasizing its AI-powered cancer detection solutions.

ICAD, Inc. Director Hedvig Hricak's stock options were converted or terminated as a result of the company's merger with RadNet, Inc., which became effective on July 17, 2025.

ICAD Chief Technology Officer Jonathan Go's beneficial ownership of common stock and stock options ceased as ICAD Inc. merged with RadNet, Inc. on July 17, 2025.

A director of ICAD, Inc. disposed of all common stock and certain stock options as a result of the company's merger with RadNet, Inc. on July 17, 2025.

ICAD Chief Financial Officer Eric Lonnqvist has reported the complete disposition of his iCAD common stock and stock options, which were converted or terminated as a result of the company's merger with RadNet, Inc. effective July 17, 2025.

ICAD, Inc. President and CEO Dana Brown's shares and eligible stock options were converted into RadNet, Inc. stock and options following the merger effective July 17, 2025.

ICAD Director Rakesh Patel reported the complete disposition of his common stock and stock options in ICAD, Inc. due to the company's merger with RadNet, Inc. on July 17, 2025.

iCAD, Inc. has filed a supplement to its definitive proxy statement for the upcoming special meeting, addressing shareholder litigation related to its proposed merger with RadNet, Inc. and providing additional financial projections.

RadNet, Inc. and iCAD, Inc. have entered into a definitive agreement for RadNet to acquire iCAD in an all-stock merger transaction.

iCAD, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, featuring proposals for director elections, equity incentive plan approval, executive compensation advisory votes, and auditor ratification.

Goldman Sachs Group and its affiliate Goldman Sachs & Co. LLC report zero beneficial ownership in ICAD, Inc. common stock as of September 30, 2025.

The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.3% beneficial ownership stake in ICAD, Inc. common stock.